Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis

Detalhes bibliográficos
Autor(a) principal: Mion,Olavo de Godoy
Data de Publicação: 2009
Outros Autores: Campos,Regis A., Antila,Martti, Rapoport,Priscila Bogar, Rosario,Nelson, Mello Junior,João Ferreira de, Guimarães,Roberto Eustáquio Santos, Mocellin,Marcos, Di Gesu,Giovanni, Solé,Dirceu, Wexler,Luc, Mello,João Ferreira de, Castro,Fábio Morato, Chavarria,Maria Letícia
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Otorhinolaryngology
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942009000500011
Resumo: Allergic rhinitis affects 10-30% of the population, negatively impacting one's quality of life and productivity. It has been associated with sinusitis, otitis media, sleep disorders, and asthma. Rupatadine is a second generation antihistamine with increased affinity to histamine receptor H1; it is also a potent PAF (platelet-activating factor) antagonist. It starts acting quite quickly, offers long lasting effect, and reduces the chronic effects of rhinitis. AIM: this study aims to assess the efficacy and safety of rupatadine in the treatment of persistent allergic rhinitis. MATERIALS AND METHOD: this is a multi-centric open prospective study. This study included 241 patients from 13 centers in Brazil and was held between October of 2004 and August of 2005. Signs and symptoms of rhinitis and tolerance to medication were analyzed after one and two weeks of treatment. RESULTS: reduction on general scores from 8.65 to 3.21 on week 2 (p<0.001). All signs and symptoms improved significantly in the first day of treatment (p<0.001), except for nasal congestion and secretion, which improved from the second day of treatment (p<0.001). Adverse events occurred in 19.9% of the cases, 27.7% on week 1. CONCLUSION: rupatadine effectively controls persistent allergic rhinitis; it is safe and presents low incidence of side effects.
id ABORL-F-1_5b4cfda6b7774123b2a2497e8c6fe4ed
oai_identifier_str oai:scielo:S1808-86942009000500011
network_acronym_str ABORL-F-1
network_name_str Brazilian Journal of Otorhinolaryngology
repository_id_str
spelling Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitisperennial allergic rhinitistherapyAllergic rhinitis affects 10-30% of the population, negatively impacting one's quality of life and productivity. It has been associated with sinusitis, otitis media, sleep disorders, and asthma. Rupatadine is a second generation antihistamine with increased affinity to histamine receptor H1; it is also a potent PAF (platelet-activating factor) antagonist. It starts acting quite quickly, offers long lasting effect, and reduces the chronic effects of rhinitis. AIM: this study aims to assess the efficacy and safety of rupatadine in the treatment of persistent allergic rhinitis. MATERIALS AND METHOD: this is a multi-centric open prospective study. This study included 241 patients from 13 centers in Brazil and was held between October of 2004 and August of 2005. Signs and symptoms of rhinitis and tolerance to medication were analyzed after one and two weeks of treatment. RESULTS: reduction on general scores from 8.65 to 3.21 on week 2 (p<0.001). All signs and symptoms improved significantly in the first day of treatment (p<0.001), except for nasal congestion and secretion, which improved from the second day of treatment (p<0.001). Adverse events occurred in 19.9% of the cases, 27.7% on week 1. CONCLUSION: rupatadine effectively controls persistent allergic rhinitis; it is safe and presents low incidence of side effects.Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial.2009-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942009000500011Brazilian Journal of Otorhinolaryngology v.75 n.5 2009reponame:Brazilian Journal of Otorhinolaryngologyinstname:Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF)instacron:ABORL-CCF10.1590/S1808-86942009000500011info:eu-repo/semantics/openAccessMion,Olavo de GodoyCampos,Regis A.Antila,MarttiRapoport,Priscila BogarRosario,NelsonMello Junior,João Ferreira deGuimarães,Roberto Eustáquio SantosMocellin,MarcosDi Gesu,GiovanniSolé,DirceuWexler,LucMello,João Ferreira deCastro,Fábio MoratoChavarria,Maria Letíciaeng2009-11-03T00:00:00Zoai:scielo:S1808-86942009000500011Revistahttp://www.bjorl.org.br/https://old.scielo.br/oai/scielo-oai.phprevista@aborlccf.org.br||revista@aborlccf.org.br1808-86861808-8686opendoar:2009-11-03T00:00Brazilian Journal of Otorhinolaryngology - Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF)false
dc.title.none.fl_str_mv Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis
title Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis
spellingShingle Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis
Mion,Olavo de Godoy
perennial allergic rhinitis
therapy
title_short Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis
title_full Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis
title_fullStr Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis
title_full_unstemmed Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis
title_sort Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis
author Mion,Olavo de Godoy
author_facet Mion,Olavo de Godoy
Campos,Regis A.
Antila,Martti
Rapoport,Priscila Bogar
Rosario,Nelson
Mello Junior,João Ferreira de
Guimarães,Roberto Eustáquio Santos
Mocellin,Marcos
Di Gesu,Giovanni
Solé,Dirceu
Wexler,Luc
Mello,João Ferreira de
Castro,Fábio Morato
Chavarria,Maria Letícia
author_role author
author2 Campos,Regis A.
Antila,Martti
Rapoport,Priscila Bogar
Rosario,Nelson
Mello Junior,João Ferreira de
Guimarães,Roberto Eustáquio Santos
Mocellin,Marcos
Di Gesu,Giovanni
Solé,Dirceu
Wexler,Luc
Mello,João Ferreira de
Castro,Fábio Morato
Chavarria,Maria Letícia
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Mion,Olavo de Godoy
Campos,Regis A.
Antila,Martti
Rapoport,Priscila Bogar
Rosario,Nelson
Mello Junior,João Ferreira de
Guimarães,Roberto Eustáquio Santos
Mocellin,Marcos
Di Gesu,Giovanni
Solé,Dirceu
Wexler,Luc
Mello,João Ferreira de
Castro,Fábio Morato
Chavarria,Maria Letícia
dc.subject.por.fl_str_mv perennial allergic rhinitis
therapy
topic perennial allergic rhinitis
therapy
description Allergic rhinitis affects 10-30% of the population, negatively impacting one's quality of life and productivity. It has been associated with sinusitis, otitis media, sleep disorders, and asthma. Rupatadine is a second generation antihistamine with increased affinity to histamine receptor H1; it is also a potent PAF (platelet-activating factor) antagonist. It starts acting quite quickly, offers long lasting effect, and reduces the chronic effects of rhinitis. AIM: this study aims to assess the efficacy and safety of rupatadine in the treatment of persistent allergic rhinitis. MATERIALS AND METHOD: this is a multi-centric open prospective study. This study included 241 patients from 13 centers in Brazil and was held between October of 2004 and August of 2005. Signs and symptoms of rhinitis and tolerance to medication were analyzed after one and two weeks of treatment. RESULTS: reduction on general scores from 8.65 to 3.21 on week 2 (p<0.001). All signs and symptoms improved significantly in the first day of treatment (p<0.001), except for nasal congestion and secretion, which improved from the second day of treatment (p<0.001). Adverse events occurred in 19.9% of the cases, 27.7% on week 1. CONCLUSION: rupatadine effectively controls persistent allergic rhinitis; it is safe and presents low incidence of side effects.
publishDate 2009
dc.date.none.fl_str_mv 2009-10-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942009000500011
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942009000500011
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1808-86942009000500011
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial.
publisher.none.fl_str_mv Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial.
dc.source.none.fl_str_mv Brazilian Journal of Otorhinolaryngology v.75 n.5 2009
reponame:Brazilian Journal of Otorhinolaryngology
instname:Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF)
instacron:ABORL-CCF
instname_str Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF)
instacron_str ABORL-CCF
institution ABORL-CCF
reponame_str Brazilian Journal of Otorhinolaryngology
collection Brazilian Journal of Otorhinolaryngology
repository.name.fl_str_mv Brazilian Journal of Otorhinolaryngology - Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF)
repository.mail.fl_str_mv revista@aborlccf.org.br||revista@aborlccf.org.br
_version_ 1754575988515143680